Linerixibat

SKU: orb1303485

Description

Linerixibat (GSK2330672) is a potent and nonabsorbable inhibitor of the apical sodium-dependent bile acid transporter (ASBT), with an IC50 of 42 ± 3 nM. It has demonstrated glucose-lowering efficacy in preclinical models of type 2 diabetes and exhibits favorable developability characteristics for research applications.

Research Area

Infectious Disease & Virology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 1345982-69-5
• MW: 546.68
• Purity: 99.99% (May vary between batches)
• Formula: C₂₈H₃₈N₂O₇S
• SMILES: CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1
• Target: HBV,ASBT
• Solubility: DMSO:21.5 mg/mL (39.33 mM)

Bioactivity

• Target IC50:
  ASBT:42 ± 3 nM

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

diabetes, Cholangitis, Biliary, aqueous, ASBT, inhibit, Inhibitor, nonabsorbable, Linerixibat, lipid-lowering, PBC, GSK 2330672, GSK2330672, GSK-2330672, hASBT, Iinerixibat, solubility, Primary, type-2

Compound Identifiers

PubChem CID

53492727